Molecular disruption of RAD50 sensitizes human tumor cells to cisplatin-based chemotherapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Molecular disruption of RAD50 sensitizes human tumor cells to cisplatin-based chemotherapy

Published:2009-07-01 Issue:7 Volume:119 Page:1974-1985
ISSN:0021-9738
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:J. Clin. Invest.

Author:

Abuzeid Waleed M.,Jiang Xiaoling,Shi Guoli,Wang Hui,Paulson David,Araki Koji,Jungreis David,Carney James,O’Malley Bert W.,Li Daqing

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Reference56 articles.

1. The resurgence of platinum-based cancer chemotherapy

2. Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair.

3. Cellular and molecular determinants of cisplatin resistance

4. Chemotherapy in advanced ovarian cancer

5. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck.

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ipatasertib, an oral AKT inhibitor, in combination with carboplatin exhibits anti-proliferative effects in uterine serous carcinoma;Annals of Medicine;2023-02-11

2. Cisplatin-induced cell death increases the degradation of the MRE11-RAD50-NBS1 complex through the autophagy/lysosomal pathway;Cell Death & Differentiation;2022-12-08

3. DNA Repair Mechanisms, Protein Interactions and Therapeutic Targeting of the MRN Complex;Cancers;2022-10-27

4. HDAC Inhibitor Sodium Butyrate Attenuates the DNA Repair in Transformed but Not in Normal Fibroblasts;International Journal of Molecular Sciences;2022-03-23

5. Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer;Cell Reports Medicine;2021-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3